Key result
Novel biomarkers of inflammation, myocardial performance, and ischemia are associated with stable angina prognosis, though a highly specific biomarker to guide treatment decisions remains lacking.
While numerous novel biomarkers are associated with stable angina prognosis, none are currently specific or clinically useful enough to guide treatment decisions.
Biomarker associations inform stable angina prognosis without guiding therapy; leaves open need for specific, validated markers in prospective trials.
Stable angina (SA) pectoris is a common and disabling disorder in patients with coronary artery disease (CAD), with increasing epidemiology and is associated with myocardial infarction and increased mortality. However, within the population of SA patients, an individual's prognosis can vary considerably. Except from conventional risk factors a variety of biomarkers have been evaluated for their prognostic significance in the settings of SA. Novel biomarkers associated with inflammatory status, such as C reactive protein and tumor necrosis factor alpha, with myocardial performance, such as B-type natriuretic peptide, with extracellular matrix remodeling, with vascular calcification such as osteoprotogerin and osteopontin, with myocardial ischemia, such as ischemia modified albumin have been associated with the progression of CAD and with the prognosis of SA patients. Despite the multiplicity of novel biomarkers there is lack of a clinical useful, highly specific for CAD biomarker with the ability to guide treatment decisions. In the context of this evidence in this review article we summarize the so far acquired knowledge of the most promising biomarkers and we discuss the major clinical correlations of novel risk factors with SA physical history, their predictive value for future cardiovascular events and their use in the treatment monitoring of this population.
No takes yet. Share an insight, caveat, or question.
Siasos et al. (2013) conducted a review in Stable angina. Novel biomarkers was evaluated. Novel biomarkers of inflammation, myocardial performance, and ischemia are associated with stable angina prognosis, though a highly specific biomarker to guide treatment decisions remains lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: